Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

Jill S. Barnholtz‐Sloan, Andrew E. Sloan, Faith G. Davis et al. · Journal of Clinical Oncology · 2004 · 1.9K citations

Medicine, Biostatistics, Oncology +15

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R. Gomez, George R. Blumenschein, Mike Hernández et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Medical Oncology +7